Darryl Penenberg

2.1k total citations · 2 hit papers
20 papers, 1.5k citations indexed

About

Darryl Penenberg is a scholar working on Oncology, Cancer Research and Surgery. According to data from OpenAlex, Darryl Penenberg has authored 20 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 6 papers in Cancer Research and 5 papers in Surgery. Recurrent topics in Darryl Penenberg's work include Pancreatic and Hepatic Oncology Research (8 papers), Cancer Genomics and Diagnostics (6 papers) and Colorectal Cancer Treatments and Studies (4 papers). Darryl Penenberg is often cited by papers focused on Pancreatic and Hepatic Oncology Research (8 papers), Cancer Genomics and Diagnostics (6 papers) and Colorectal Cancer Treatments and Studies (4 papers). Darryl Penenberg collaborates with scholars based in United States, Canada and Spain. Darryl Penenberg's co-authors include Howard I. Scher, Alan Yagoda, Nancy L. Geller, Alfredo Romano, Werner Scheithauer, Daniel D. Von Hoff, Josep Tabernero, David Goldstein, Pramod C. Sogani and Lora Weiselberg and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Darryl Penenberg

19 papers receiving 1.4k citations

Hit Papers

Methotrexate, vinblastine, doxorubicin, and cisplatin for... 1989 2026 2001 2013 1989 2015 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse
    1989 540 citations Cora N. Sternberg, Alan Yagoda et al. Cancer profile →
  2. nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
    2015 504 citations David Goldstein, Robert H. El-Maraghi et al. JNCI Journal of the National Cancer Institute profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Darryl Penenberg United States 9 799 758 356 258 240 20 1.5k
Steven W. Warmann Germany 25 390 0.5× 673 0.9× 497 1.4× 196 0.8× 177 0.7× 144 1.9k
Simon Cleall United Kingdom 10 604 0.8× 1.5k 2.0× 344 1.0× 205 0.8× 99 0.4× 17 2.0k
Joyce Antal United States 19 1.1k 1.4× 552 0.7× 552 1.6× 157 0.6× 104 0.4× 33 1.8k
Eijiro Nakamura Japan 19 574 0.7× 233 0.3× 472 1.3× 92 0.4× 241 1.0× 59 1.4k
Tzong‐Shin Tzai Taiwan 21 253 0.3× 425 0.6× 252 0.7× 68 0.3× 128 0.5× 81 1.2k
D W Day United Kingdom 15 803 1.0× 467 0.6× 441 1.2× 254 1.0× 93 0.4× 25 1.5k
Stratigoula Sakellariou Greece 19 398 0.5× 286 0.4× 224 0.6× 271 1.1× 245 1.0× 77 1.3k
Chun‐Shu Lin Taiwan 23 304 0.4× 362 0.5× 371 1.0× 213 0.8× 211 0.9× 87 1.4k
Jesco Pfitzenmaier Germany 21 390 0.5× 265 0.3× 753 2.1× 71 0.3× 277 1.2× 58 1.6k
Andrew T. Lenis United States 18 399 0.5× 1.2k 1.6× 652 1.8× 112 0.4× 321 1.3× 77 2.1k

Countries citing papers authored by Darryl Penenberg

Since Specialization
Citations

This map shows the geographic impact of Darryl Penenberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Darryl Penenberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Darryl Penenberg more than expected).

Fields of papers citing papers by Darryl Penenberg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Darryl Penenberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Darryl Penenberg. The network helps show where Darryl Penenberg may publish in the future.

Co-authorship network of co-authors of Darryl Penenberg

This figure shows the co-authorship network connecting the top 25 collaborators of Darryl Penenberg. A scholar is included among the top collaborators of Darryl Penenberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Darryl Penenberg. Darryl Penenberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sandborn, William J., Brian G. Feagan, Geert D’Haens, et al.. (2017). Safety and Efficacy of Long-term Treatment With Ozanimod: An Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis - TOUCHSTONE Extension 2-Year Follow-up. The American Journal of Gastroenterology. 112. S321–S321. 5 indexed citations
2.
Feagan, Brian G., William J. Sandborn, Silvio Danese, et al.. (2017). Endoscopic and Clinical Efficacy Demonstrated With Oral Ozanimod in Moderately to Severely Active Crohnʼs Disease. The American Journal of Gastroenterology. 112. S371–S371. 4 indexed citations
3.
Sandborn, William J., Brian G. Feagan, Geert D’Haens, et al.. (2017). OP014 Histological remission is predictive of improved clinical outcomes in patients with ulcerative colitis: results from the TOUCHSTONE open-label extension. Journal of Crohn s and Colitis. 11(suppl_1). S9–S9. 2 indexed citations
4.
Dellon, Evan S., Margaret H. Collins, Larry Evans, et al.. (2016). A Randomized, Double-Blind, Placebo-Controlled Trial of a Novel Recombinant, Humanized, Anti-Interleukin-13 Monoclonal Antibody (RPC4046) in Patients with Active Eosinophilic Esophagitis: Results of the HEROES Study. The American Journal of Gastroenterology. 111(S1). S186–S186. 17 indexed citations
5.
Penenberg, Darryl. (2016). Exposure–Response Modeling Methods and Practical Implementation. Journal of the Royal Statistical Society Series A (Statistics in Society). 179(3). 881–882. 1 indexed citations
6.
Penenberg, Darryl. (2016). Mathematical Statistics: Basic Ideas and Selected Topics, 2nd edn, vols I and II. Journal of the Royal Statistical Society Series A (Statistics in Society). 179(4). 1128–1129. 4 indexed citations
7.
Goldstein, David, Robert H. El-Maraghi, Pascal Hammel, et al.. (2015). nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial. JNCI Journal of the National Cancer Institute. 107(2). dju413–dju413. 504 indexed citations breakdown →
8.
Tabernero, Josep, E. Gabriela Chiorean, Jeffrey R. Infante, et al.. (2015). Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer. The Oncologist. 20(2). 143–150. 110 indexed citations
9.
Kunzmann, Volker, Ramesh K. Ramanathan, David Goldstein, et al.. (2015). Tumor reduction in pancreatic versus metastatic sites in a randomized phase III study (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone.. Journal of Clinical Oncology. 33(3_suppl). 382–382. 1 indexed citations
10.
11.
12.
Binder, G., Dejan Milentijevic, Darryl Penenberg, et al.. (2014). Budget Impact of Albumin-Bound Paclitaxel + Gemcitabine in the Treatment of Metastatic Pancreatic Cancer. Value in Health. 17(3). A74–A74. 1 indexed citations
13.
14.
15.
Viscusi, Eugene R., James P. Rathmell, Alessandro Fichera, et al.. (2013). Randomized placebo-controlled study of intravenous methylnaltrexone in postoperative ileus. PubMed. 2(1). 127–134. 18 indexed citations
16.
Penenberg, Darryl, et al.. (2000). The Effects of Hepatic Impairment on the Pharmacokinetics of Doxazosin. The Journal of Clinical Pharmacology. 40(1). 67–73. 3 indexed citations
17.
Alderman, Jeffrey, Sheldon Preskorn, David J. Greenblatt, et al.. (1997). Desipramine Pharmacokinetics When Coadministered With Paroxetine or Sertraline in Extensive Metabolizers. Journal of Clinical Psychopharmacology. 17(4). 284–291. 97 indexed citations
18.
19.
LaQuaglia, Michael P., Fereshteh Ghavimi, Darryl Penenberg, et al.. (1990). Factors predictive of mortality in pediatric extremity rhabdomyosarcoma. Journal of Pediatric Surgery. 25(2). 238–244. 34 indexed citations
20.
Sternberg, Cora N., Alan Yagoda, Howard I. Scher, et al.. (1989). Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer. 64(12). 2448–2458. 540 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Steven W. Warmann Breakdown of academic impact, for papers by Simon Cleall Breakdown of academic impact, for papers by Joyce Antal Breakdown of academic impact, for papers by Eijiro Nakamura Breakdown of academic impact, for papers by Tzong‐Shin Tzai Breakdown of academic impact, for papers by D W Day Breakdown of academic impact, for papers by Stratigoula Sakellariou Breakdown of academic impact, for papers by Chun‐Shu Lin Breakdown of academic impact, for papers by Jesco Pfitzenmaier Breakdown of academic impact, for papers by Andrew T. Lenis
Rankless by CCL
2026